Daewoong Pharmaceutical announced plans to construct a sterile manufacturing facility for microneedles at its Daewoong Bio Plant 3 in Hyangnam, Hwaseong-si, Gyeonggi-do. This new infrastructure will support the production of microneedle-based pharmaceutical products. The investment aims to bolster Daewoong’s capabilities in advanced drug delivery systems and expand its presence in the biotechnology sector. The company anticipates increased production capacity and improved quality control through this facility. This expansion signifies Daewoong Pharmaceutical’s commitment to innovation and meeting growing market demands. The facility will adhere to stringent sterile manufacturing standards, ensuring product safety and efficacy. The new plant is expected to be a key component of Daewoong’s future growth strategy in the pharmaceutical industry.